Access cutting-edge alpha-1 antitrypsin deficiency treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access alpha-1 antitrypsin deficiency specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alpha-1 antitrypsin deficiency treatment provided free
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works
Sponsor: Takeda
Check if you qualify for this alpha-1 antitrypsin deficiency clinical trial in Los Angeles, CA
If you're searching for alpha-1 antitrypsin deficiency treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alpha-1 antitrypsin deficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.